Navigation Links
Daytrana (methylphenidate transdermal system) Provides Significant,Effectiveness in ADHD Symptom Relief in Both Boys and Girls

SAN DIEGO, May 23, 2007 /PRNewswire-FirstCall/ -- Shire plc announced today that DAYTRANA(TM) (methylphenidate transdermal system), its Attention Deficit Hyperactivity Disorder (ADHD) patch, had significant efficacy in reducing the symptoms of ADHD in both male and female children aged 6 to 12 years, according to clinical trial results reported at the American Psychiatric Association (APA) annual meeting in San Diego.

"Few clinical studies have examined gender differences in the response to ADHD treatments. Our study documented that DAYTRANA offered a favorable safety profile and was an effective ADHD treatment in both boys and girls," said Robert Findling, M.D., lead investigator and Professor of Psychiatry at and Director of the Division of Adolescent and Child Psychiatry at University Hospitals Case Medical Center. "The study provides a platform to open a dialogue about gender and ADHD."

Approximately 4.4 million U.S. children aged 4 to 17 years -- about 7.8 percent of all school-age children -- have been diagnosed with ADHD at some point in their lives, according to the U.S. Centers for Disease Control and Prevention (CDC). Studies estimated that 11.0 percent of boys have been diagnosed with ADHD in contrast to only 4.4 percent of girls. Experts believe that girls with ADHD are underdiagnosed and, therefore, undertreated.

Shire's DAYTRANA is the first and only patch medication approved by the U.S. Food and Drug Administration (FDA) to treat the symptoms of ADHD in children aged 6 to 12 years. DAYTRANA is available in four dosage strengths - 10 mg, 15 mg, 20 mg and 30 mg - all designed for once-daily use. When worn for the recommended nine hours, efficacy has been demonstrated from the first time point measured (two hours) through the 12-hour time point. Because Daytrana is a patch, physicians may recommend that patients shorten the wear time if shorter duration of effect is desired or t
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. 12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA (methylphenidate transdermal system)
2. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
3. XTL Provides Update on Phase I Clinical Trial of XTL-2125
4. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
5. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
6. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
7. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
8. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
9. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
10. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
11. Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data Show
Post Your Comments:
(Date:8/28/2015)... WARRENVILLE, Ill. , Aug. 28, 2015 /PRNewswire/ ... Patterson Companies, Inc. (Nasdaq: PDCO ), is ... the previously announced acquisition of Patterson Medical by ... Medical will retain its name for a transition ... distributor of rehabilitation and sports medicine products.  With ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... announced the addition of the "Investigation Report on ... Developed by Novartis, ranibizumab was approved by ... in 2012. Currently, only Lucentis, a product of Novartis, ... 2013, as the first self- developed drug for the ...
(Date:8/28/2015)... , Aug. 28, 2015  Perrigo Company plc ("Perrigo") ... has completed the acquisition of leading OTC brands from ... million. The transaction is a clear demonstration of Perrigo,s ... leading European distribution network spanning 36 countries.  ... Papa commented, "We are excited to complete this ...
Breaking Medicine Technology:Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
... Medical, Inc., the global leader in devices for clot ... Merci Retriever® has recently received both product and procedure ... Welfare.  The Merci Retriever is a catheter-based medical device ... clots from the brains of patients suffering an ischemic ...
... BEDMINSTER, N.J., Oct. 4 Archimedes Pharma US Inc. ... study of Fentanyl Pectin Nasal Spray (FPNS) in the ... "A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin ... pain," has been published in Pain , the ...
Cached Medicine Technology:Concentric Medical Announces Product and Procedure Reimbursement as Well as Full Commercialization of the Merci Retriever® in Japan 2Concentric Medical Announces Product and Procedure Reimbursement as Well as Full Commercialization of the Merci Retriever® in Japan 3Archimedes Pharma Announces Publication of a Pivotal Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in Pain, the Peer-Reviewed Journal from the International Association for the Study of Pain 2Archimedes Pharma Announces Publication of a Pivotal Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in Pain, the Peer-Reviewed Journal from the International Association for the Study of Pain 3
(Date:8/28/2015)... ... , ... The Kentucky State Department of Workforce Investment Commissioner Beth Kuhn recently ... for, they are unable to pass the initial drug test and therefore unable to ... order to be able to hire long-term, skilled talent. (1) Will Wesch, Director of ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Understanding the FDA’s Position and Best Practices for Compliance, **Presented by FDAnews ... This workshop, chaired by internationally renowned expert Fubin Wu, has been specifically ...
(Date:8/28/2015)... Michigan (PRWEB) , ... August 28, 2015 , ... ... alcohol abuse, or those who might personally be struggling with chemical dependency, may ... post from Best Drug Rehabilitation, a results-driven holistic treatment center for addiction located ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new approach on solutions ... it should begin with the employer and employees getting together for meaningful group ...
(Date:8/28/2015)... ... August 28, 2015 , ... Dr. Gregory K. Toumayan, D.C., Q.M.E., is now ... shoulder pain, hip pain, neck pain, stiffness, muscle spasms, and numbness. ... of Illinois, and then went on to earn his title of Doctor of Chiropractic ...
Breaking Medicine News(10 mins):Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3
... found an effective two-part treatment for microtears in the hamstring: ... with "dry-needling," in which repeated needle punctures cause controlled internal ... presented today at the annual meeting of the Radiological Society ... blood where it is needed at the site of a ...
... In the wake of multiple state bans on caffeinated ... to remove their products from the marketplace, an article published ... the scope of the public health problem and suggests areas ... manufacturers of caffeinated beer have withdrawn their products from the ...
... , ROCHESTER, Minn. - A team of Mayo Clinic researchers ... as apical ballooning syndrome (ABS), have blood vessels that don,t ... cause of this rare syndrome and may help with efforts ... so that appropriate therapies can be developed. The study is ...
... Through an innovative use of cell phone records, researchers at ... found that women appear to avoid contact with their fathers ... frequently on these high-fertility days and they hang up with ... Haselton, a UCLA associate professor of communication in whose lab ...
... By Jenifer Goodwin HealthDay Reporter , MONDAY, ... in children and teens over the last few decades, with ... youths, according to a new report. In one startling ... for Healthcare Research and Quality found that hospitalizations for eating ...
... HealthDay Reporter , MONDAY, Nov. 29 (HealthDay News) -- ... function for the "love hormone" oxytocin in human behavior. ... naturally occurring chemical, recalled intensified fond memories of their mothers ... men initially reported less close relationships with Mom, oxytocin seemed ...
Cached Medicine News:Health News:Researchers use patient's own blood to treat hamstring injury 2Health News:Caffeinated alcoholic beverages -- a growing public health problem 2Health News:Abnormal blood vessel function found in women with broken heart syndrome 2Health News:Contact with dads drops when women ovulate 2Health News:Contact with dads drops when women ovulate 3Health News:Contact with dads drops when women ovulate 4Health News:Rate of Eating Disorders in Kids Keeps Rising 2Health News:Rate of Eating Disorders in Kids Keeps Rising 3Health News:'Love Hormone' Boosts Memories of Mom -- Good or Bad, Study Finds 2Health News:'Love Hormone' Boosts Memories of Mom -- Good or Bad, Study Finds 3
... The Raindrop® medication nebulizer achieves optimum lung ... particle size range is 1.04-1.10 µ at ... or air outlet., ,As the world ... healthcare providers the assurance of proven technology ...
... Eliminate the need for makeshift, modified nebulizer ... waste time gathering parts when your patient ... to deliver the utmost in Heliox rescue ... is fast becoming the standard of care ...
... World's smallest nebulizer utilizing Vibrating ... medications for patients suffering from Asthma, ... appreciate the small product size and ... transported wherever life takes them. Powerful ...
... as well as humidification, try Flo-Mist™., ... volume, continuous medication nebulizer (CMN), engineered to ... 200 ml reservoir and jet flow design ... nebulized medication delivery at 25 ml/hr. Particles ...
Medicine Products: